Heart failure & cardiomyopathies
Efficacy and Safety of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction: Systematic Review
Authors' conclusion
The results show that BAT is safe and improves functional class, quality of life and congestion in selected patients with HFrEF.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF)2 RCTs
- Comparison
- Baroreflex activation therapy (BAT) vs pharmacological treatment
- Outcome
- NYHA functional class, quality of life, 6-min walk test, NT-proBNP
Methodological detailsRisk of bias by Cochrane RoB2; certainty by GRADE, Fixed- or random-effects model depending on heterogeneity
- Risk of bias by Cochrane RoB2; certainty by GRADE
- Fixed- or random-effects model depending on heterogeneity
Pooled result
As reported in the abstract
BAT vs Pharmacological treatmentRelative risk (95% CI)
NYHA functional class improvement
2.13(1.65–2.76)
BAT vs Pharmacological treatmentDifference in means (95% CI)
Quality of life
−16.97(−21.87 to −12.07)
6-min walk test
56.54(55.67–57.41)
NT-proBNP
−120.02(−193.58 to −46.45)
Safety
System- and procedure-related complication event-free rate
- Event-free rate range across studies
- 85.9% to 97%
Original publication
Efficacy and Safety of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction: Systematic Review. ESC Heart Fail. Published 31 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →